Max Chat
Calendrier des promotions Co-Diagnostics, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Paramètres de base
IPO date
2017-07-12
ISIN
US1897631057
Industry
Health Care Equipment & Supplies
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 5.42 | 2 |
| P/BV | 0.3909 | 10 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -47.25 | 0 |
| ROE | -53.65 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.0556 | 10 |
| Debt/Ratio | 0.0336 | 10 |
| Debt/Equity | 0.1784 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | -94.75 | 0 |
| Rentabilité Ebitda, % | -190.64 | 0 |
| Rentabilité EPS, % | -181.63 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 0.2758 $ | 0 $ | 0 $ | 0.07 % | 0 % | 0 % |
| common.calendar.number_days.7d | 0.295 $ | 0 $ | 0 $ | -6.44 % | 0 % | 0 % |
| common.calendar.number_days.30d | 0.2316 $ | 0.2758 $ | 0.3001 $ | 19.17 % | 0 % | 0 % |
| common.calendar.number_days.90d | 0.369 $ | 0.2316 $ | 0.375 $ | -25.2 % | 0 % | 0 % |
| common.calendar.number_days.180d | 0.6876 $ | 0.2316 $ | 0.84 $ | -59.86 % | 0 % | 0 % |
| common.calendar.number_days.1y | 1.57 $ | 0.2316 $ | 1.75 $ | -82.42 % | 0 % | 0 % |
| common.calendar.number_days.3y | 3.52 $ | 0.2316 $ | 7.01 $ | -92.16 % | 0 % | 0 % |
| common.calendar.number_days.5y | 28.38 $ | 0.2316 $ | 30.8 $ | -99.03 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0.2316 $ | 0.2316 $ | 30.8 $ | 119.08 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 0.735 $ | 0.2316 $ | 1 $ | -62.45 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Mr. Dwight H. Egan | Chairman & CEO | 415.75k | 1953 (72 année) |
| Mr. Brian L. Brown CPA | CFO & Company Secretary | 338.92k | 1976 (49 années) |
| Dr. Brent C. Satterfield Ph.D. | Co-Founder & Member of Scientific Advisory Board | 237.5k | 1977 (48 années) |
| Mr. Dan Bohrer CPA | Vice President of Finance & Accounting | N/A | |
| Mr. Andrew Benson | Head of Investor Relations | N/A | |
| Dr. Mayuranki Almaula | Senior Vice President of Overseas Operations & Strategic Alliances | N/A | |
| Mr. Richard David Abbott | President | N/A | 1972 (53 année) |
| Mr. David Nielsen | Chief Operating Officer | N/A | |
| Mr. Christopher Thurston | Chief Technology Officer | N/A | |
| Mr. Cameron Gundry | Head of Commercialization LATAM/EUR |
Informations sur l'entreprise
Adresse: United States, Salt Lake City. UT, 2401 South Foothill Drive - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.codiagnostics.com
Site web: https://www.codiagnostics.com
